Fresenius Medical Care

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

VR Medical, established in 2009, is a US-based manufacturer that specializes in providing low-cost, high-quality medical devices. The company supports medical device manufacturers and distributors by offering a comprehensive solution for new product development, contract manufacturing, and secure product distribution in China. VR Medical's focus includes disposable products and electronic devices tailored for private labels, serving various medical markets such as respiratory care, critical care, blood purification, and advanced wound care. Through its innovative approach, the company enables clients to enhance their offerings while maintaining efficiency and cost-effectiveness in the production process.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

BioIntellisense, Inc., established in 2018 and headquartered in Golden, Colorado, specializes in healthcare devices and data services for continuous remote health monitoring. The company's core products are the BioButton and BioSticker, both FDA-cleared wearable medical devices. These devices seamlessly collect multi-parameter vital signs, physiological biometrics, and symptomatic events, enabling predictive analytics and algorithmic clinical insights. The data is channeled to the company's medical-grade Data-as-a-Service (DaaS) platform, providing high-resolution patient trending and reporting to clinicians, facilitating medical-grade care from the hospital to the home.

SafeRide Health is a healthcare technology platform that focuses on enhancing medical transportation and care coordination for vulnerable populations. The company provides a comprehensive platform that empowers health plans to manage their members effectively, ensuring greater intelligence and control over services. By utilizing advanced technology and artificial intelligence, SafeRide Health facilitates end-to-end data transparency, which in turn improves patient experiences and outcomes. The platform aims to transform the patient journey, enhance population health, and reduce overall healthcare costs through its innovative solutions, including patented fleet management capabilities tailored to the healthcare industry.

Modulim is a leader in light-based imaging technology focused on tissue and vascular assessment through spatial frequency domain imaging (SFDI). The company has developed the Clarifi Imaging System, which aids clinicians in identifying patients at risk for complications such as diabetic foot ulcers and amputations due to compromised circulation. By enabling timely interventions, this technology plays a crucial role in preserving patients' limbs and lives. Additionally, Modulim's devices are applicable in research, aesthetics, and medicine, providing professionals with transformative tools for the prevention, diagnosis, and treatment of various medical skin conditions.

Tridiuum, Inc. is a Philadelphia-based digital health company established in 1997 that specializes in software-as-a-service solutions for behavioral health providers, patients, and health systems. The core offering, Tridiuum1, is a cloud-based platform designed to enhance behavioral health outcomes management by monitoring patient symptoms and treatment progress. It integrates digital health assessments with an analytics engine to identify behavioral health issues, assign risk scores, and provide real-time alerts at the point of care. Additionally, the platform supports video-based virtual visits and other features, enabling clinicians to effectively evaluate and manage patients with various conditions. The company is backed by a team of experts in behavioral medicine and digital health technologies, with a strong foundation in clinical research and a history of contributions to peer-reviewed scientific literature.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, established in 2011. The company specializes in developing and manufacturing advanced cardiac monitoring systems for patients with congestive heart failure. Its flagship product, the V-LAP, is the world's first in-heart microcomputer that provides daily, push-button readings of left atrial pressure (LAP), the earliest and most reliable indicator of heart failure deterioration. This innovative device is miniature, wireless, and battery-less, allowing it to communicate effectively from within the body. Vectorious is currently conducting clinical trials in several European countries, including Italy, Germany, and the UK, aiming to obtain a CE mark for its product. Additionally, plans for a clinical study in the United States were anticipated to commence in 2020. Through its technology, Vectorious aims to enhance the quality of life and life expectancy for individuals suffering from heart failure.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, established in 2011. The company specializes in developing and manufacturing advanced cardiac monitoring systems for patients with congestive heart failure. Its flagship product, the V-LAP, is the world's first in-heart microcomputer that provides daily, push-button readings of left atrial pressure (LAP), the earliest and most reliable indicator of heart failure deterioration. This innovative device is miniature, wireless, and battery-less, allowing it to communicate effectively from within the body. Vectorious is currently conducting clinical trials in several European countries, including Italy, Germany, and the UK, aiming to obtain a CE mark for its product. Additionally, plans for a clinical study in the United States were anticipated to commence in 2020. Through its technology, Vectorious aims to enhance the quality of life and life expectancy for individuals suffering from heart failure.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

Modulim is a leader in light-based imaging technology focused on tissue and vascular assessment through spatial frequency domain imaging (SFDI). The company has developed the Clarifi Imaging System, which aids clinicians in identifying patients at risk for complications such as diabetic foot ulcers and amputations due to compromised circulation. By enabling timely interventions, this technology plays a crucial role in preserving patients' limbs and lives. Additionally, Modulim's devices are applicable in research, aesthetics, and medicine, providing professionals with transformative tools for the prevention, diagnosis, and treatment of various medical skin conditions.

NxStage Medical, Inc., established in 1998 and headquartered in Lawrence, Massachusetts, specializes in the development, manufacturing, and marketing of medical technologies for treating end-stage renal disease (ESRD) and acute kidney failure. The company's primary product is the System One, a portable hemodialysis system designed for home use. Additionally, NxStage offers water purification systems, chronic cartridges for flexible renal replacement therapy, and a telehealth platform called Nx2me Connected Health. The company also provides a range of disposable products such as bloodlines, needles, and dialysis fluids, along with dialysis services and operates dialysis centers. Since February 2019, NxStage has been a subsidiary of Fresenius Medical Care Holdings, Inc.

Cura Group is a prominent provider of day hospital facilities in Australia, established in 2008. The company operates private hospital facilities that focus on day procedures, specializing in various medical fields such as ophthalmology, plastic, reconstructive and cosmetic surgery, orthopedic surgery, oral surgery, and pediatric services. By concentrating on these areas, Cura Group aims to enhance patient health and streamline the surgical process, providing quality care in a more efficient setting.

XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company offers a comprehensive range of products, including the iLA active platform for extrapulmonary lung support, iLA Membrane Ventilator for pumpless lung support, and various cannulas and pumps designed for cardiac surgery applications. Additionally, XENiOS provides innovative solutions such as the NovaTherm Heater/Cooler for blood temperature management and the deltastream series for monitoring and managing patient parameters during treatment. The company is uniquely positioned in the market by offering minimally invasive, disposable therapies that address both lung and heart conditions on a single platform, which is not available from other manufacturers. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG also delivers clinical application support, training, and customer service to healthcare providers. As of late 2016, it operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.

Sparsh Nephrocare focuses on making dialysis treatment accessible to kidney failure patients throughout India and South East Asia. It operates in-hospital dialysis units and standalone dialysis therapy centers, utilizing advanced machines and employing well-trained technicians. The company has introduced innovative concepts such as the in-hospital dialysis center and has established dialysis facilities through Public Private Partnership (PPP) models with leading government institutions. By managing the complete operations of these centers and ensuring that all medical records are stored electronically in compliance with NABH norms, Sparsh Nephrocare aims to alleviate the operational burdens faced by hospital management. The organization is committed to creating a comprehensive ecosystem that enhances the accessibility and quality of renal care for patients in the region.

National Cardiovascular Partners specializes in providing endovascular, vascular, and cardiovascular services in outpatient settings. The company operates 21 outpatient vascular centers across six states, collaborating with over 200 physicians. NCP focuses on independent outpatient cardiac catheterization and vascular labs, where physician entrepreneurs serve as majority stakeholders, retaining clinical and financial control of their practices. Meanwhile, NCP manages the administrative and back-office operations, allowing physicians to prioritize high-quality patient care. This model fosters innovative healthcare delivery while ensuring efficient operational support.

Sound Physicians is a healthcare company focused on enhancing the quality of inpatient care through its network of over 1,000 hospitalist and post-acute physicians. The company partners with more than 70 hospitals and an increasing number of post-acute care centers across the United States. It provides a range of services that span the acute episode of care, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By offering these comprehensive solutions, Sound Physicians aims to improve patient satisfaction and financial performance for its hospital partners, ultimately driving better outcomes in healthcare delivery.

MedSpring is a walk in clinic when someone needs a immediate medical care.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company dedicated to delivering coordinated, outcomes-based medical care in a cost-effective manner. The company emphasizes high-quality medical care and effective population health management, particularly for senior patients and those with multiple chronic conditions. Through its healthcare delivery segment, Astrana Health focuses on enhancing care coordination among physicians and leveraging a network of support services to improve patient outcomes while managing healthcare costs. By prioritizing the needs of both patients and physicians, Astrana Health aims to advance the quality of care within the evolving landscape of value-based healthcare.

Liberty Dialysis, LLC, headquartered in Mercer Island, Washington, specializes in the development, ownership, and operation of dialysis clinics across the United States. Established in 2002, the company serves patients with chronic kidney disease by offering outreach programs and home dialysis options. Liberty Dialysis operates numerous clinics in states including Alaska, California, Colorado, and more, aiming to deliver optimal care through patient education and advanced technology. As of February 2012, Liberty Dialysis is a subsidiary of Fresenius Medical Care AG & Co. KGAA, enhancing its capacity to provide comprehensive renal care.

American Access Care is a hospital & health care company that provides dialysis access management services.

Renal Advantage Inc. is a Brentwood, Tennessee-based provider of outpatient dialysis services, focusing on patients with chronic kidney ailments. The company operates over 154 freestanding renal dialysis centers across the United States. Founded by experienced healthcare executives, Renal Advantage emphasizes a Center-Centric operating philosophy, which aims to enhance the experiences of both patients and healthcare professionals. By prioritizing high-quality care, Renal Advantage seeks to improve the quality of life for its patients while fostering positive relationships with partners and staff.

Hema Metrics is a medical monitoring devices company. Hema Metrics serves thousands of patients worldwide and provides products for more than 1 million treatments each year.

Xcorporeal is a medical device company focused on creating innovative products designed to replace failing or failed organs. The company specializes in developing an extra-corporeal platform technology that can be utilized in devices aimed at restoring the functionality of various human organs. Through its advancements, Xcorporeal seeks to address critical health challenges associated with organ failure, providing solutions that enhance patient care and outcomes.

Renal Solutions is a company based in Warrendale, Pennsylvania, that specializes in the development of dialysis products and services. Founded in 2000 and acquired by Fresenius Medical Care in 2007, the company focuses on creating integrated medical devices for sorbent hemodialysis treatment. These devices provide a clinical care model tailored for patients with chronic and acute kidney failure, allowing healthcare practitioners to offer flexible and convenient treatment options. Renal Solutions aims to enhance renal care through innovative sorbent-based dialysis technologies.

Jiate Excelsior Co., Ltd. provides dialysis services for treating hemodialysis patients.

Renal Care Group, Inc. provides dialysis services to patients with chronic kidney failure, also known as end-stage renal disease (ESRD). It provides its services for the treatment of chronic and acute renal diseases. The company also provides ancillary service, which is the administration of erythropoietin, also known as Epogen, a bioengineered protein that stimulates the production of red blood cells. As of December 31, 2005, Renal Care Group operated 456 outpatient dialysis centers in 34 states with 7,894 certified dialysis stations and provided inpatient dialysis services to approximately 200 acute care hospitals. The company was founded in 1996 and is headquartered in Nashville, Tennessee. As of March 31, 2006, Renal Care Group, Inc. is a subsidiary of Fresenius Medical Care AG & Co. KGAA.